Video Latest - ecancer

We should use PDL1 and other biomarkers for selecting patients for immune checkpoint therapies

Dr Mary O’Brien - The Royal Marsden NHS Foundation Trust, London, UK

5 Oct 2016

Using PDL1 and other biomarkers in patient selection for immunology: Q & A

Dr O'Brien and Prof McVie

5 Oct 2016

Imaging and novel PET tracers: Q & A

Dr Giulia Veronesi and Prof Tony Ng

5 Oct 2016

Imaging and novel PET tracers: The future

Prof Tony Ng - King's College London, London, UK

5 Oct 2016

Imaging and novel PET tracers: State of the art

Dr Giulia Veronesi - Humanitas Research Hospital, Milan, Italy

5 Oct 2016

Editor's Choice for September 2016

Prof Gordon McVie - Editor in Chief, ecancer

3 Oct 2016

Proton therapy in the UK: The Newport clinic

Dr Jamie Powell - Proton Partners International, Newport, UK

29 Sep 2016

Advances and investment in modern proton therapy

Dr Hernán Cortés-Funes - HC Marbella, Marbella, Spain

29 Sep 2016

Proton accelerators for cancer therapy

Dr Stephen Myers - AVO, Geneva, Switzerland

28 Sep 2016

When is an assay ready for the clinic?

Dr Erasmus Schneider - Wadsworth Center, Albany, USA

28 Sep 2016

Building a succesful proton therapy centre

Prof James Metz - University of Pennsylvania, Philadelphia, USA

27 Sep 2016

Practical implementation of proton therapy in the UK

Prof Karol Sikora - Proton Partners International, Cardiff, UK

27 Sep 2016

Video